These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 30741059

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis.
    Salas MQ, Prem S, Remberger M, Lam W, Kim DDH, Michelis FV, Al-Shaibani Z, Gerbitz A, Lipton JH, Viswabandya A, Kumar R, Kumar D, Mattsson J, Law AD.
    Leuk Lymphoma; 2020 Dec; 61(13):3198-3208. PubMed ID: 32715815
    [Abstract] [Full Text] [Related]

  • 43. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice.
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients.
    Kumar D, Patil N, Husain S, Chaparro C, Bhat M, Kim SJ, Humar A.
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28489256
    [Abstract] [Full Text] [Related]

  • 51. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH, Meylan P, ESCMID Study Group of Infection in Compromised Hosts.
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [Abstract] [Full Text] [Related]

  • 52. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Niu YY, Dong YJ, Yin Y, Xu WL, Liang ZY, Wang Q, Li Y, Liu W, Ou JP, Ren HY.
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov 14; 42(11):904-910. PubMed ID: 35045651
    [Abstract] [Full Text] [Related]

  • 53. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M, Goodyear D, Geddes MN, Liu S, Ugarte-Torres A, Liu Y, Walker JT, Fonseca K, Daly A, Duggan P, Stewart D, Russell JA, Storek J.
    Bone Marrow Transplant; 2011 Aug 14; 46(8):1104-12. PubMed ID: 21057556
    [Abstract] [Full Text] [Related]

  • 54. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 14; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 55. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia.
    Hyun H, Park E, Cho M, Min SI, Ha J, Kang HJ, Shin HY, Ha IS, Cheong HI, Ahn YH, Kang HG.
    J Korean Med Sci; 2019 Aug 05; 34(30):e203. PubMed ID: 31373185
    [Abstract] [Full Text] [Related]

  • 56. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC, Akinwumi MS, Cervera C, Mabilangan C, Ghosh S, Lai R, Iafolla M, Doucette K, Preiksaitis JK.
    Transplantation; 2018 Sep 05; 102(9):1553-1562. PubMed ID: 29485513
    [Abstract] [Full Text] [Related]

  • 57. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.
    Zhu K, Chen J, Chen S.
    Hematology; 2005 Oct 05; 10(5):365-70. PubMed ID: 16273722
    [Abstract] [Full Text] [Related]

  • 58. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.
    Dumas PY, Ruggeri A, Robin M, Crotta A, Abraham J, Forcade E, Bay JO, Michallet M, Bertrand Y, Socié G, Ionescu I, Gluckman E, Milpied N, Rocha V.
    Bone Marrow Transplant; 2013 Feb 05; 48(2):253-6. PubMed ID: 22773124
    [Abstract] [Full Text] [Related]

  • 59. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M, Husain S, Famure O, Li Y, Kim SJ.
    Prog Transplant; 2019 Jun 05; 29(2):185-193. PubMed ID: 30845885
    [Abstract] [Full Text] [Related]

  • 60. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation.
    Jain T, Kosiorek HE, Grys TE, Kung ST, Shah VS, Betcher JA, Slack JL, Leis JF, Khera N, Noel P, Palmer JM, Sproat LZ.
    Leuk Lymphoma; 2019 Jan 05; 60(1):110-117. PubMed ID: 29979906
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.